SCM
INO icon

Sterling Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

Sterling Capital Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-624
Closed -$1.02K – 3321
2025
Q1 		$1.02K Sell
624
-258
-29% -$518 ﹤0.01% 2809
2024
Q4 		$1.61K Buy
882
+801
+989% +$3.54K ﹤0.01% 2834
2024
Q3 		$468 Buy
+81
New +$668 ﹤0.01% 2904

Other funds holding INO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sterling Capital Management's INO Position: Q2 2025 in Review

Sterling Capital Management sold out of Inovio Pharmaceuticals (INO) in Q2 2025, closing a stake of 624 shares — an estimated $1.02K sold.

Sterling Capital Management first reported a position in INO in Q3 2024 and held it in 3 quarters. The position peaked at $1.61K in Q4 2024. 103 funds tracked by Wall St. Rank hold INO as of Q2 2025.

  • Sterling Capital Management reported no remaining Inovio Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Sterling Capital Management sold 624 Inovio Pharmaceuticals shares in Q2 2025, an estimated $1.02K.
  • Sterling Capital Management first reported a position in Inovio Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Sterling Capital Management's Inovio Pharmaceuticals position peaked at $1.61K in Q4 2024.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2025.

Based on Sterling Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.